fda glp-1 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System FDA Approves First Generic GLP-1
Description
Earlier readout in non-diabetics showed ~12.4% , at the lower end of expectationsstill clinically meaningful but shy of leading injectables
This further enhances the credibility of our conclusions
But given the strength of the trial data, it's a development worth watching closely
Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression
